Therapy2

[M1VID1] Criteria for selecting mCRPC suitable to receive the maximum benefit from Ra-223 treatment

Kazuhiro Kitajima¹、Junpei Kuyama²、Takashi Kawahara³、Tsuyoshi Suga⁴、Tomoaki Otani⁵、Shigeyasu Sugawara⁶、Yumiko Kono⁷、Yukihisa Tamaki⁸、Ayumi Seko⁹、Yoshinobu Ishiwata^{10 11 12 13 14 15} (1.Department of Radiology, Hyogo College of Medicine, Hyogo, Japan、2.Department of Nuclear Medicine, Chiba Cancer Center, Chiba, Japan、3.Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan、4.Department of Radiology, Kobe City Medical Center General Hospital, Kobe, Japan、5.Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan、6.Department of Advanced Clinical Research Center, Fukushima Medical University, Fukushima, Japan、7.Department of Radiology, Kansai Medical University, Osaka, Japan、8.Department of Radiology, Shimane University, Faculty of Medicine, Shimane, Japan、9.Department of Radiology, Shiga University of Medical Science, Shiga, Japan、10.Department of Radiology, Yokohama City Universuty Scool of Medicine, Kanagawa 236-0004, Japan、11.、12.、13.、14.、15.)